Improved health-related quality of life after hepatitis C viraemic clearance among people who inject drugs may not be durable.
Direct-acting antivirals
PWID
Scotland
health-related quality of life
hepatitis C virus
sustained virological response
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
11
08
2022
accepted:
07
02
2023
medline:
14
6
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Chronic infection with the hepatitis C virus (HCV) has a detrimental impact on health-related quality of life (QoL). Scale-up of HCV direct-acting antiviral (DAA) therapy among people who inject drugs (PWID) is underway in several countries since the introduction of interferon-free regimens. This study aimed to assess the impact of DAA treatment success on QoL for PWID. Cross-sectional study using two rounds of the Needle Exchange Surveillance Initiative, a national anonymous bio-behavioural survey and a longitudinal study involving PWID who underwent DAA therapy. The setting for the cross-sectional study was Scotland (2017-2018, 2019-2020). The setting for the longitudinal study was the Tayside region of Scotland (2019-2021). In the cross-sectional study PWID were recruited from services providing injecting equipment (n = 4009). In the longitudinal study, participants were PWID on DAA therapy (n = 83). In the cross-sectional study, the association between QoL (measured using the EQ-5D-5L quality of life instrument) and HCV diagnosis and treatment was assessed using multilevel linear regression. In the longitudinal study, QoL was compared at four timepoints using multilevel regression, from treatment commencement until 12 months following commencement. In the cross-sectional study, 41% (n = 1618) were ever chronically HCV infected, of whom 78% (n = 1262) were aware of their status and of whom 64% (n = 704) had undergone DAA therapy. There was no evidence for a marked QoL improvement associated with viral clearance among those treated for HCV (B = 0.03; 95% CI, -0.03 to 0.09). In the longitudinal study, improved QoL was observed at the sustained virologic response test timepoint (B = 0.18; 95% CI, 0.10-0.27), but this was not maintained at 12 months following start of treatment (B = 0.02; 95% CI, -0.05 to 0.10). Successful direct-acting antiviral therapy for hepatitis C infection may not lead to a durable improvement in quality of life among people who inject drugs, although there may be a transient improvement around the time of sustained virologic response. Economic models of the impact of scaling-up treatment may need to include more conservative quality of life benefits over and above reductions in mortality, disease progression and transmission of infection.
Sections du résumé
BACKGROUND AND AIMS
Chronic infection with the hepatitis C virus (HCV) has a detrimental impact on health-related quality of life (QoL). Scale-up of HCV direct-acting antiviral (DAA) therapy among people who inject drugs (PWID) is underway in several countries since the introduction of interferon-free regimens. This study aimed to assess the impact of DAA treatment success on QoL for PWID.
DESIGN
Cross-sectional study using two rounds of the Needle Exchange Surveillance Initiative, a national anonymous bio-behavioural survey and a longitudinal study involving PWID who underwent DAA therapy.
SETTING
The setting for the cross-sectional study was Scotland (2017-2018, 2019-2020). The setting for the longitudinal study was the Tayside region of Scotland (2019-2021).
PARTICIPANTS
In the cross-sectional study PWID were recruited from services providing injecting equipment (n = 4009). In the longitudinal study, participants were PWID on DAA therapy (n = 83).
MEASUREMENTS
In the cross-sectional study, the association between QoL (measured using the EQ-5D-5L quality of life instrument) and HCV diagnosis and treatment was assessed using multilevel linear regression. In the longitudinal study, QoL was compared at four timepoints using multilevel regression, from treatment commencement until 12 months following commencement.
FINDINGS
In the cross-sectional study, 41% (n = 1618) were ever chronically HCV infected, of whom 78% (n = 1262) were aware of their status and of whom 64% (n = 704) had undergone DAA therapy. There was no evidence for a marked QoL improvement associated with viral clearance among those treated for HCV (B = 0.03; 95% CI, -0.03 to 0.09). In the longitudinal study, improved QoL was observed at the sustained virologic response test timepoint (B = 0.18; 95% CI, 0.10-0.27), but this was not maintained at 12 months following start of treatment (B = 0.02; 95% CI, -0.05 to 0.10).
CONCLUSIONS
Successful direct-acting antiviral therapy for hepatitis C infection may not lead to a durable improvement in quality of life among people who inject drugs, although there may be a transient improvement around the time of sustained virologic response. Economic models of the impact of scaling-up treatment may need to include more conservative quality of life benefits over and above reductions in mortality, disease progression and transmission of infection.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1340-1350Subventions
Organisme : Medical Research Council
ID : MR/N00616X/1
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0616-20 008
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Références
Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27(1):209-12. https://doi.org/10.1002/hep.510270132
Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology. 2005;41(4):790-800. https://doi.org/10.1002/hep.20659
Doyle JS, Grebely J, Spelman T, Alavi M, Matthews GV, Thompson AJ, et al. Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-Centre prospective cohort. PLoS ONE. 2016;11(6):e0150655. https://doi.org/10.1371/journal.pone.0150655
Stepanova M, Thompson A, Doyle J, Younossi I, De Avila L, Younossi ZM. Hepatitis C virus-infected patients receiving opioid substitution therapy experience improvement in patient-reported outcomes following treatment with interferon-free regimens. J Infect Dis. 2017;217(7):1033-43. https://doi.org/10.1093/infdis/jix681
Hutchinson SJ, Valerio H, McDonald SA, Yeung A, Pollock K, Smith S, et al. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: A national record-linkage study. Gut. 2020;69(12):2223-31. https://doi.org/10.1136/gutjnl-2019-320007
Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, et al. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe)-a natural experiment (protocol). BMJ Open. 2019;9(9):e029538. https://doi.org/10.1136/bmjopen-2019-029538
Palmateer NE, McAuley A, Dillon JF, McDonald S, Yeung A, Smith S, et al. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: Real-world data. Addiction. 2021;16(10):2893-907. https://doi.org/10.1111/add.15459
Byrne CJ, Beer L, Inglis SK, Robinson E, Radley A, Goldberg DJ, et al. Real-world outcomes of rapid regional hepatitis C virus treatment scale-up among people who inject drugs in Tayside. Scotland Aliment Pharmacol Therap. 2022;55(5):568-79. https://doi.org/10.1111/apt.16728
Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, et al. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol. 2016;65(1):17-25. https://doi.org/10.1016/j.jhep.2016.02.007
Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49-57. https://doi.org/10.1002/hep.24656
Younossi Z, Henry L. Systematic review: Patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens. Aliment Pharmacol Therap. 2015;41(6):497-520. https://doi.org/10.1111/apt.13090
Juanbeltz R, Castilla J, Martínez-Baz I, O'Leary A, Sarobe M, San MR. Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: A comparison with the general population. Qual Life Res. 2019;28(6):1477-84. https://doi.org/10.1007/s11136-019-02111-1
Dusheiko G. The impact of antiviral therapy for hepatitis C on the quality of life: A perspective. Liver Int. 2017;37:7-12. https://doi.org/10.1111/liv.13292
McDonald SA, Hutchinson SJ, Palmateer NE, Allen E, Cameron SO, Goldberg DJ, et al. Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. J Hepatol. 2013;58(3):460-6. https://doi.org/10.1016/j.jhep.2012.11.004
Health Protection Scotland (HPS), University of the West of Scotland, Glasgow Caledonian University and West of Scotland Specialist Virology Centre. Needle exchange surveillance initiative (NESI): 2008-09 to 2017-18 Glasgow: HPS; 2019.
EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208. https://doi.org/10.1016/0168-8510(90)90421-9
Nosyk B, Sun H, Guh DP, Oviedo-Joekes E, Marsh DC, Brissette S, et al. The quality of eight health status measures were compared for chronic opioid dependence. J Clin Epidemiol. 2010;63(10):1132-44. https://doi.org/10.1016/j.jclinepi.2009.12.003
Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708-15. https://doi.org/10.1016/j.jval.2012.02.008
McLeod A, Glancy M, Went A, Smith S, Weir A, McAuley A, et al. HPS surveillance report: Surveillance of hepatitis C testing, diagnosis and treatment in Scotland, 2019 update Health Protection Scotland; 2019.
Heinze G, Wallisch C, Dunkler D. Variable selection-a review and recommendations for the practicing statistician. Biom J. 2018;60(3):431-49. https://doi.org/10.1002/bimj.201700067
Dunkler D, Plischke M, Leffondré K, Heinze G. Augmented backward elimination: A pragmatic and purposeful way to develop statistical models. PLoS ONE. 2014;9(11):e113677. https://doi.org/10.1371/journal.pone.0113677
R Core Team. R: A language and environment for statistical computing Vienna, Austria: R Foundation for Statistical Computing; 2018 URL http://www.R-project.org/
StataCorp. Stata 16 Base Reference Manual College Station, TX: Stata Press; 2019.
Gormley MA, Akiyama MJ, Rennert L, Howard KA, Norton BL, Pericot-Valverde I, et al. Changes in health-related quality of life for hepatitis C virus-infected people who inject drugs while on opioid agonist treatment following sustained virologic response. Clin Infect Dis. 2022;74(9):1586-93. https://doi.org/10.1093/cid/ciab669
Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, et al. Survival and cessation in injecting drug users: Prospective observational study of outcomes and effect of opiate substitution treatment. BMJ. 2010;341(jul01 1):c3172. https://doi.org/10.1136/bmj.c3172
Rand K, Arnevik EA, Walderhaug E. Quality of life among patients seeking treatment for substance use disorder, as measured with the EQ-5D-3L. J Patient-Reported Outc. 2020;4(1):92, 1-10. https://doi.org/10.1186/s41687-020-00247-0
Dalgard O, Egeland A, Skaug K, Vilimas K, Steen T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology. 2004;39(1):74-80. https://doi.org/10.1002/hep.20014
Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6(5):578-82. https://doi.org/10.1038/75063
Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: Another step toward consensus. J Clin Epidemiol. 2005;58(12):1217-9. https://doi.org/10.1016/j.jclinepi.2005.07.009
Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care. 2003;41(5):582-92. https://doi.org/10.1097/01.MLR.0000062554.74615.4C
Linas BP, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, et al. Cost effectiveness and cost containment in the era of interferon-free therapies to treat hepatitis C virus genotype 1. Open forum. Infect Dis. 2017;4:ofw266.
Barbosa C, Fraser H, Hoerger TJ, Leib A, Havens JR, Young A, et al. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Addiction. 2019;114(12):2267-78. https://doi.org/10.1111/add.14731
Van Santen DK, de Vos AS, Matser A, Willemse SB, Lindenburg K, Kretzschmar ME, et al. Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, the Netherlands. PLoS ONE. 2016;11(10):e0163488. https://doi.org/10.1371/journal.pone.0163488
Lawson KD, Mercer SW, Wyke S, Grieve E, Guthrie B, Watt G, et al. Double trouble: The impact of multimorbidity and deprivation on preference-weighted health related quality of life a cross sectional analysis of the Scottish health survey. Int J Equity Health. 2013;12(1):1-9. https://doi.org/10.1186/1475-9276-12-67